-->

Tech Seeker (TS)

Actelion Ltd
Profile last edited on: 9/21/2015

NO Business Identifier is currently available for this company.
TS Type
N/A
Status
Year Founded
1997
Last Involved Year
2016

Key People / Management

  Jean-Paul Clozel -- President

Location Information

Gewerberstrasse 16
Allschwil, SW
   41 61 565 65 65
   www.actelion.com

Public Profile

Actelion Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for diseases with unmet medical needs. It offers Tracleer, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH), a chronic and life-threatening disorder that severely compromises the functions of the lungs and heart; and Opsumit, an orally available endothelin receptor antagonist for the treatment of PAH to delay disease progression. The company also provides Veletri, an intravenous prostacyclin for the treatment of PAH to enhance exercise capacity; and Ventavis, an inhaled synthetic analog of prostacyclin for the treatment of PAH to enhance a composite endpoint consisting of exercise tolerance, symptoms, and lack of deterioration. In addition, it offers Valchlor, a chemotherapeutic agent for the treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients; and Zavesca, an oral treatment for patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable. Actelion Ltd markets its products in Switzerland, the United States, Europe, Japan, China, Russia, Mexico, and internationally. The company was founded in 1997 and is headquartered in Allschwil, Switzerland.

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Headquartered
Switzerland
Employment
2,495
Revenue
$0.0B
Public/Private
Publicly Traded
Stock Info
OTC : ALIOF
Received SBIR $$
No

SBIR firms in the news

There are no news available.